{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:23:11Z","timestamp":1787768591524,"version":"build-2784847793"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background and purpose:<\/jats:title>\n                    <jats:p>Treatment of malignancies with chemotherapy and surgery is often associated with disease recurrence and metastasis. Immunotherapy improves cancer treatment by creating an active response against tumor antigens. Various cancer cells express a large amount of glucose-regulated protein 78 (GRP78) protein on their surface. Stimulating the immune system against this antigen can expose cancer cells to the immune system. Herein, we investigated the effectiveness of a cGRP78-based vaccine against different cancer cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental approach:<\/jats:title>\n                    <jats:p>BALB\/c mice were immunized with the cGRP78. The humoral immune response against different cancer cells was assessed by Cell-ELISA. The cellular immunity response was determined by splenocyte proliferation assay with different cancer antigens. The effect of vaccination on metastasis was investigated in vaccinated mice by injecting melanoma cancer cells into the tail of mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings\/Results:<\/jats:title>\n                    <jats:p>These results indicated that the cGRP78 has acceptable antigenicity and stimulates the immune system to produce antibodies. After three injections, the amount of produced antibody was significantly different from the control group. Compared to the other three cell types, Hela and HepG2 showed the highest reaction to the serum of vaccinated mice. Cellular immunity against the B16F10 cell line had the best results compared to other cells. The metastasis results showed that after 30 days, the growth of B16F10 melanoma cancer cells was not noticeable in the lung tissue of vaccinated mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and implications:<\/jats:title>\n                    <jats:p>Considering the resistance of vaccinated mice to metastasis, this vaccine offers a promising prospect for cancer treatment by inhibiting the spread of cancer cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/1735-5362.394822","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T07:30:23Z","timestamp":1706081423000},"page":"73-82","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Investigating the effect of cGRP78 vaccine against different cancer cells and its role in reducing melanoma metastasis"],"prefix":"10.4103","volume":"19","author":[{"given":"Hamed","family":"Zare","sequence":"first","affiliation":[{"name":"Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Bakherad","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran."},{"name":"Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman Nasr","family":"Esfahani","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Aghamollaei","sequence":"additional","affiliation":[{"name":"Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Latif Mousavi","family":"Gargari","sequence":"additional","affiliation":[{"name":"Department of Biology, Faculty of Basic Science, Shahed University, Tehran, I.R. Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Aliomrani","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Isfahan Pharmaceutical Science Research Center, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walead","family":"Ebrahimizadeh","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Urology, McGill University and the Research Institute of the McGill University Health Centre (RI MUHC), Montreal, Quebec, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"issue":"1","key":"R1-20240909","first-page":"26","article-title":"Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice","volume":"21","author":"Gheybi","year":"2018","journal-title":"Iran J Basic Med Sci"},{"issue":"1","key":"R2-20240909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"5","key":"R3-20240909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.soncn.2019.08.002","article-title":"Cancer and the immune system: the history and background of immunotherapy","volume":"35","author":"Abbott","year":"2019","journal-title":"Semin Oncol Nurs"},{"issue":"2","key":"R4-20240909","first-page":"293","article-title":"Tumour-associated macrophage polarisation and re-education with immunotherapy","volume":"7","author":"Josephs","year":"2015","journal-title":"Front Biosci (Elite Ed)"},{"issue":"3","key":"R5-20240909","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/107327481001700307","article-title":"Developing an effective breast cancer vaccine","volume":"17","author":"Soliman","year":"2010","journal-title":"Cancer Control"},{"issue":"1","key":"R6-20240909","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1073\/pnas.1115166109","article-title":"Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine","volume":"109","author":"Lakshminarayanan","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"564136","key":"R7-20240909","first-page":"1","article-title":"Synergistic effects of toxic elements on heat shock proteins","volume":"2014","author":"Mahmood","year":"2014","journal-title":"Biomed Res Int"},{"issue":"2","key":"R8-20240909","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/bab.1916","article-title":"Isolation and characterization of a novel nanobody for detection of GRP78 expressing cancer cells","volume":"68","author":"Aghamollaei","year":"2021","journal-title":"Biotechnol Appl Biochem"},{"key":"R9-20240909","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jconrel.2020.10.055","article-title":"Cell surface GRP78: an emerging imaging marker and therapeutic target for cancer","volume":"328","author":"Farshbaf","year":"2020","journal-title":"J Control Release"},{"issue":"6","key":"R10-20240909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-018-0669-8","article-title":"Betulinic acid chemosensitizes breast cancer by triggering ER stress-mediated apoptosis by directly targeting GRP78","volume":"9","author":"Cai","year":"2018","journal-title":"Cell Death Dis"},{"issue":"1","key":"R11-20240909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-021-02786-6","article-title":"GRP78 in lung cancer","volume":"19","author":"Xia","year":"2021","journal-title":"J Transl Med"},{"issue":"1","key":"R12-20240909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2018.02.007","article-title":"GRP78 Promotes hepatocellular carcinoma proliferation by increasing FAT10 expression through the NF-\u03baB pathway","volume":"365","author":"Luo","year":"2018","journal-title":"Exp Cell Res"},{"issue":"5","key":"R13-20240909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2020.12125","article-title":"LINC00294 induced by GRP78 promotes cervical cancer development by promoting cell cycle transition","volume":"20","author":"Qiu","year":"2020","journal-title":"Oncol Lett"},{"issue":"6","key":"R14-20240909","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/iub.2502","article-title":"Glucose-regulated protein (GRP78) is an important cell surface receptor for viral invasion, cancers, and neurological disorders","volume":"73","author":"Gonzalez-Gronow","year":"2021","journal-title":"IUBMB life"},{"issue":"6","key":"R15-20240909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biomedicines10061222","article-title":"Physiological roles of the autoantibodies to the 78-kilodalton glucose-regulated protein (GRP78) in cancer and autoimmune diseases","volume":"10","author":"Gonzalez-Gronow","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"R16-20240909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biomedicines10061350","article-title":"Isoliquiritigenin inhibits gastric cancer sternness, modulates tumor microenvironment, and suppresses tumor growth through glucose-regulated protein 78 downregulation","volume":"10","author":"Lee","year":"2022","journal-title":"Biomedicines"},{"issue":"829520","key":"R17-20240909","first-page":"1","article-title":"HSP70 and HSP90 in cancer: cytosolic, endoplasmic reticulum and mitochondrial chaperones of tumorigenesis","volume":"12","author":"Albakova","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"R18-20240909","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2174\/1389450118666170615100918","article-title":"GRP78 influences chemoresistance and prognosis in cancer","volume":"19","author":"Gifford","year":"2018","journal-title":"Curr Drug Targets"},{"issue":"1","key":"R19-20240909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-10824-7","article-title":"The deubiquitylase OTUD3 stabilizes GRP78 and promotes lung tumorigenesis","volume":"10","author":"Du","year":"2019","journal-title":"Nat Commun"},{"issue":"5","key":"R20-20240909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0125634","article-title":"Cell surface GRP78 accelerated breast cancer cell proliferation and migration by activating STAT3","volume":"10","author":"Yao","year":"2015","journal-title":"PloS One"},{"issue":"1","key":"R21-20240909","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/bab.1455","article-title":"Structure prediction, expression, and antigenicity of c-terminal of GRP78","volume":"64","author":"Aghamollaei","year":"2017","journal-title":"Biotechnol Appl Biochem"},{"key":"R22-20240909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.10.004","article-title":"Linking cell-surface GRP78 to cancer: from basic research to clinical value of GRP78 antibodies","volume":"524","author":"Hernandez","year":"2022","journal-title":"Cancer Lett"},{"issue":"6","key":"R23-20240909","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4103\/1735-5362.245965","article-title":"Anti-melanogenesis and anti-tyrosinase properties of Pistacia atlantica subsp. mutica extracts on B16F10 murine melanoma cells","volume":"13","author":"Eghbali-Feriz","year":"2018","journal-title":"Res Pharm Sci"},{"issue":"4","key":"R24-20240909","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4103\/1735-5362.293516","article-title":"Expression of recombinant G-CSF receptor domains and their inhibitory role on G-CSF function","volume":"15","author":"Bakherad","year":"2020","journal-title":"Res Pharm Sci"},{"issue":"1","key":"R25-20240909","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/CMR.0b013e3283426805","article-title":"Autoantibodies against cell-surface GRP78 promote tumor growth in a murine model of melanoma","volume":"21","author":"de","year":"2011","journal-title":"Melanoma Res"},{"issue":"4","key":"R26-20240909","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.4049\/jimmunol.171.4.1809","article-title":"IL-18 stimulates the proliferation and IFN-\u03b3 release of CD4+ T cells in the chicken: conservation of a Th1-like system in a nonmammalian species","volume":"171","author":"G\u00f6bel","year":"2003","journal-title":"J Immunol"},{"issue":"5","key":"R27-20240909","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood.V96.5.1857","article-title":"Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte responses","volume":"96","author":"Herr","year":"2000","journal-title":"Blood"},{"issue":"11","key":"R28-20240909","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41684-021-00871-3","article-title":"Guideline for the care and use of laboratory animals in Iran","volume":"50","author":"Ahmadi-Noorbakhsh","year":"2021","journal-title":"Lab Anim (NY)"},{"issue":"9","key":"R29-20240909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0071216","article-title":"Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects","volume":"8","author":"Cheng","year":"2013","journal-title":"PloS One"},{"issue":"9","key":"R30-20240909","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2174\/156652412803306684","article-title":"Heat shock proteins (HSPs) based anti-cancer vaccines","volume":"12","author":"Ciocca","year":"2012","journal-title":"Curr Mol Med"},{"issue":"1","key":"R31-20240909","doi-asserted-by":"crossref","first-page":"45","DOI":"10.15171\/bi.2019.06","article-title":"In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens","volume":"9","author":"Parvizpour","year":"2019","journal-title":"BioImpacts"},{"issue":"270","key":"R32-20240909","first-page":"1","article-title":"Breast cancer vaccines: new insights","volume":"8","author":"Benedetti","year":"2017","journal-title":"Front Endocrinol"},{"issue":"5","key":"R33-20240909","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1158\/1535-7163.MCT-08-0990","article-title":"Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis","volume":"8","author":"Misra","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"24","key":"R34-20240909","doi-asserted-by":"crossref","first-page":"6802","DOI":"10.1158\/1078-0432.CCR-13-1106","article-title":"Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K\/AKT signaling, tumor growth, and metastasis","volume":"19","author":"Liu","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"R35-20240909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-18572-3","article-title":"Local anesthetic lidocaine-inducible gene, growth differentiation factor-15 suppresses the growth of cancer cell lines","volume":"12","author":"Haraguchi-Suzuki","year":"2022","journal-title":"Sci Rep"},{"issue":"11","key":"R36-20240909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells10112996","article-title":"Similarities and differences of Hsp70, hsc70, Grp78 and mortalin as cancer biomarkers and drug targets","volume":"10","author":"Rai","year":"2021","journal-title":"Cells"},{"issue":"2472","key":"R37-20240909","first-page":"1","article-title":"The Immunogenicity and anti-tumor efficacy of a rationally designed neoantigen vaccine for B16F10 mouse melanoma","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"issue":"9","key":"R38-20240909","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/sj.cgt.7701072","article-title":"mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes","volume":"14","author":"Mockey","year":"2007","journal-title":"Cancer Gene Ther"}],"container-title":["Research in Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/1735-5362.394822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:16:09Z","timestamp":1787768169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1735-5362.394822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/1735-5362.394822","relation":{},"ISSN":["1735-5362","1735-9414"],"issn-type":[{"value":"1735-5362","type":"print"},{"value":"1735-9414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2022-12-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}